By NewsDesk @infectiousdiseasenews
Researchers at the University of Oxford on Monday launched a Phase 1 trial to test a new vaccine against plague.
Based on the ChAdOx1 adenovirus viral vector platform also used in the successful Oxford coronavirus vaccine, forty healthy adults aged 18 to 55 will receive this new vaccine in order to assess side effects and determine how well it induces protective antibody and T cell responses.
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group, said:
‘The coronavirus pandemic has shown the importance of vaccines to defend populations from the threat caused by bacteria and viruses. Plague threatened the world in several horrific waves over past millennia, and, even today, outbreaks continue to disrupt communities. A new vaccine to prevent plague is important for them and for our health security.’
Probably the most well-known example of plague is the Black Death of the 1300s; this form of the bubonic plague was the biggest global pandemic in history and killed hundreds of millions of people worldwide.
Read more at University of Oxford
- Shingles vaccine, Shingrix, gets FDA approval for prevention in immunocompromised adults
- Antibiotics: DALVANCE receives FDA approval
- Powassan virus: 2nd case reported in Maine in 2021
- Brazil yellow fever: Human death recorded in Amapá state, Monkey deaths in Santa Catarina
- Riyadh man is Saudi Arabia’s 10th MERS case of 2021
- Recovered COVID-19 patients retain broad and effective longer-term immunity to the disease: Emory study
- Malaria in Malaysia: Plasmodium cynomolgi human infections widely distributed according to researchers
- Thailand reports record 15K COVID-19 cases Sunday